Redwood Investment Management LLC Invests $2.26 Million in DaVita Inc. $DVA

Redwood Investment Management LLC bought a new stake in DaVita Inc. (NYSE:DVA) in the 2nd quarter, Holdings Channel reports. The firm bought 10,145 shares of the company’s stock, valued at approximately $2,257,000.

Other institutional investors have also added to or reduced their stakes in the company. Root Financial Partners LLC lifted its stake in DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after acquiring an additional 105 shares during the last quarter. Caitlin John LLC bought a new position in shares of DaVita in the 4th quarter valued at about $34,000. Sankala Group LLC acquired a new position in shares of DaVita during the 4th quarter worth about $39,000. Canada Pension Plan Investment Board bought a new stake in shares of DaVita in the 2nd quarter valued at about $43,000. Finally, Kestra Advisory Services LLC bought a new stake in shares of DaVita in the 4th quarter valued at about $45,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.90% of the stock is currently owned by corporate insiders.

DaVita Trading Up 1.4%

NYSE DVA opened at $180.34 on Thursday. The company has a 50 day moving average of $213.07 and a 200-day moving average of $182.80. The company has a market cap of $11.51 billion, a price-to-earnings ratio of 14.76, a PEG ratio of 0.59 and a beta of 0.88. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $247.49.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. During the same quarter last year, the business posted $2.95 EPS. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities research analysts forecast that DaVita Inc. will post 14.57 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. TD Cowen upgraded DaVita from a “hold” rating to a “buy” rating and lifted their price target for the stock from $201.00 to $220.00 in a report on Friday, August 7th. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Barclays lifted their target price on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Truist Financial cut their price target on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th. Finally, Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $221.75.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.